A Phase 1 interventional study of nirsevimab and Placebo in Evaluate PK Profile, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-02.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the Pharmacokinetics, Safety, Tolerability of Nirsevimab in Healthy Chinese Adults.
This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the PK, safety and tolerability, and ADA of nirsevimab when administered as a single fixed IM dosage to healthy Chinese adult subjects. Enrolment is planned at a single study center in China. Approximately 24 subjects will be randomly assigned in a 3:1 ratio to receive nirsevimab (n = 18) or placebo (n = 6). All subjects will be followed for approximately 150 days after dosing to assess safety, PK, and ADA response.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nirsevimab single dose IM injection
Biological: nirsevimab
Placebo single dose IM injection
Other: Placebo
Drug: injection, a single fixed IM dose on day 1 only.
Also known as: MEDI8897
Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
Serum Concentrations of Nirsevimab
Serum samples were collected at indicated timepoints to determine the serum concentration of nirsevimab.
Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose.
Maximum Observed Serum Concentration (Cmax) for Nirsevimab
Cmax for nirsevimab was directly calculated from the individual concentration-time curve.
Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose
Time to Reach Maximum Observed Serum Concentration (Tmax) for Nirsevimab
Tmax for nirsevimab was directly calculated from the individual concentration-time curve.
Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose
Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab
Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab was calculated by linear up/log down trapezoidal summation.
Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose
Number of Participants With Positive Anti-Drug Antibody (ADA) of Nirsevimab
ADA positive was defined as any participant with a positive ADA result available at any time, including baseline and all post-baseline measurements; otherwise ADA negative.
Time frame: Baseline (Day 1) and Days 31, 91 and 151
This was a Phase 1, placebo-controlled, study to evaluate pharmacokinetics (PK), safety, and tolerability of nirsevimab compared to placebo in healthy participants conducted at a single center in China.
| Milestone | Nirsevimab | Placebo |
|---|---|---|
| Started | 18 | 6 |
| Completed | 18 | 6 |
| Not completed | 0 | 0 |
Serum samples were collected at indicated timepoints to determine the serum concentration of nirsevimab.
| micrograms/milliliter (mcg/mL) | Nirsevimab |
|---|---|
| Pre-dose Day 1 | NA ± NA |
| Day 2 | 27.644 ± 5.819 |
| Day 4 | 41.794 ± 8.447 |
| Day 6 | 43.811 ± 8.291 |
| Day 8 | 46.050 ± 12.484 |
| Day 15 | 43.739 ± 7.236 |
| Day 31 | 40.300 ± 5.391 |
| Day 91 | 25.200 ± 3.694 |
| Day 151 | 17.597 ± 3.854 |
Cmax for nirsevimab was directly calculated from the individual concentration-time curve.
| mcg/mL | Nirsevimab |
|---|---|
| Maximum Observed Serum Concentration (Cmax) for Nirsevimab | 46.882 ± 21.7 |
Tmax for nirsevimab was directly calculated from the individual concentration-time curve.
| days | Nirsevimab |
|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) for Nirsevimab | 6.99 (4.91 to 29.90) |
Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab was calculated by linear up/log down trapezoidal summation.
| mcg*day/mL | Nirsevimab |
|---|---|
| Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab | 4210.56 ± 13.6 |
ADA positive was defined as any participant with a positive ADA result available at any time, including baseline and all post-baseline measurements; otherwise ADA negative.
| Participants | Nirsevimab |
|---|---|
| Baseline (Day 1) | 0 |
| Day 31 | 0 |
| Day 91 | 0 |
| Day 151 | 0 |
Collected over Treatment emergent adverse events were collected from first date of study treatment administration (Day 1) up to 151 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nirsevimab | 0/18 (0%) | 0/18 (0%) | 5/18 (27.8%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Nirsevimab | Placebo |
|---|---|---|
| Haemoglobin decreasedInvestigations | 1/18 | 1/6 |
| Blood bilirubin increasedInvestigations | 0/18 | 1/6 |
| Urobilinogen urine increasedInvestigations | 2/18 | 0/6 |
| Blood creatinine increasedInvestigations | 1/18 | 0/6 |
| Complement factor decreasedInvestigations | 1/18 | 0/6 |
| Platelet count decreasedInvestigations | 1/18 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 0/6 |
As-treated population included all participants who were randomized into the study and received any amount of study treatment.
| Age, Continuous(years) | Nirsevimab | Placebo | Total |
|---|---|---|---|
| Mean | 29.2 ± 5.55 | 29.8 ± 4.71 | 29.3 ± 5.26 |
| Sex: Female, Male(Participants) | Nirsevimab | Placebo | Total |
|---|---|---|---|
| Female | 3 | 4 | 7 |
| Male | 15 | 2 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Nirsevimab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 18 | 6 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Nirsevimab | Placebo | Total |
|---|---|---|---|
| Asian | 18 | 6 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2021 to primary completion in Nov 2021, 4 months.
Results were first posted in Nov 2023, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nirsevimab